Clinical trials: Skin Diseases, Viral
Melanoma
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxic T Lymphocyte Antigen 4…
- Trial name
- NCT01400451
- Testing
- Ipilimumab (BMS-734016), Vemurafenib
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Bristol-Myers Squibb
Common Warts
Carbon Dioxide Laser and Cryotherapy in Treatment of Warts
Viral warts are common skin conditions seen in both children and adults. Human papilloma virus is responsible for verrucae. Cutaneous manifestation of the human papillomavirus, are extremely common particularly on the hands and…
- Trial name
- NCT03166137
- Testing
- Carbon dioxide laser, Cryotherapy
- Volunteers
- 60 people
- Sponsor
- Assiut University
HIV Infection, Mitochondrial Dysfunction
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1.
- Trial name
- NCT01194856
- Testing
- Atazanavir/ritonavir, Efavirenz
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Cleveland Clinic
Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
This phase II trial is studying how well imatinib mesylate works in treating patients with metastatic or unresectable Merkel cell cancer.
- Conditions
- Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin, Stage III Neuroendocrine Carcinoma of the Skin
- Trial name
- NCT00068783
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Drug-Drug Interaction Study: ASP2151 and Ritonavir
ASP2151 is an experimental treatment for herpes. HIV infected people are susceptible to contracting other infections because of their compromised immune system.
- Trial name
- NCT02223351
- Testing
- ASP2151, ritonavir
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
WHIM Syndrome
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not…
- Trial name
- NCT03087370
- Testing
- No intervention
- Sponsor
- X4 Pharmaceuticals
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Palmar or Plantar Warts
Nonavalent HPV Vaccine in the Treatment of Difficult-to-treat Palmo-plantar Warts
Cutaneous viral warts are very common and are caused by the human papilloma virus (HPV). Most people experience warts in one form or another at some point in their lives. Cutaneous warts are related to different types of HPV.
- Trial name
- VAC-WARTS (NCT04814446)
- Testing
- Vaccination
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections
PREventing Progression of Adipose Tissue Redistribution
The main objective of the study is to assess changes in fat distribution over 48 weeks of treatment in patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen and who will either…
- Trial name
- NCT00389194
- Testing
- continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
Rheumatoid Arthritis, Chronic Hepatitis B
Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background
The purpose of this study is to investigate whether the combination of abatacept along with entecavir (the study drugs) is safe and effective in treating symptoms related to rheumatoid arthritis (RA).
- Trial name
- RA (NCT02053727)
- Testing
- Abatacept
- Where
- United States
- Sponsor
- University of California, Los Angeles
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Intense-exuberant Stomach Fire Syndrom, Acute Pericoronitis
Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome
This clinical research focus on evaluating the effectiveness of Huanglian-Jiedu Decoction in patients with intense-exuberant stomach fire syndrome (one of the common TCM syndrome)of acute pericoronitis,minor recurrent aphthous…
- Conditions
- Intense-exuberant Stomach Fire Syndrom, Acute Pericoronitis, Recurrent Aphthous Stomatitis, Recurrent Herpes Simplex Labialis
- Trial name
- NCT03469232
- Testing
- Huanglian-Jiedu Decoction
- Where
- 3 sites in China
- Volunteers
- 240 people
- Sponsor
- China Academy of Chinese Medical Sciences
Covid-19 Infection, Rheumatoid Arthritis
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking…
- Conditions
- Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis, Hydroxychloroquine
- Trial name
- IMPACT (NCT04347798)
- Testing
- Hydroxychloroquine/Chloroquine
- Where
- Canada
- Volunteers
- 773 people
- Sponsor
- University of Alberta
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Psoriasis, Covid19
PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis
To determine if there is a need for further education on vaccines with psoriasis patients who are on a biologic. In regards to the COVID-19, it is important that psoriasis patients - whether on a biologic or not - understand…
- Trial name
- NCT04513847
- Where
- Canada
- Volunteers
- 661 people
- Sponsor
- Dermatrials Research
Warts
Multicenter Real-World Study of Hyperthermia in Warts of Special Population
Hyperthermia refers to treating diseases with temperatures beyond normal body temperature (39-45℃), and moxibustion therapy of traditional Chinese medicine belongs to the category of hyperthermia.
- Trial name
- NCT06827938
- Testing
- YY-WRY-V01 Infrared thermotherapy apparatus
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Hospital of China Medical University
Covid19
COVID-19 Vaccine Hesitancy Among Rheumatic Diseases Patients
Rheumatological diseases (RD) are an important group of different clinical entities and specific diseases that affect a significant proportion of the world population.
- Trial name
- NCT04775563
- Testing
- COVID-19 vaccine hesitancy scale in rheumatic diseases, COVID-19 vaccine hesitancy associated factors
- Where
- Mexico
- Volunteers
- 891 people
- Sponsor
- National Institute of Medical Sciences and Nutrition, Salvador Zubiran
Rheumatic Diseases
Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection
SAR-COVID is a national, multicenter, prospective, observational longitudinal registry of consecutive patients with diagnosis of rheumatic diseases treated or not with immunomodulatory and/or immunosuppressive drugs and…
- Trial name
- SAR-COVID (NCT04568421)
- Testing
- Immunosuppressive Agents
- Where
- Argentina
- Volunteers
- 2,982 people
- Sponsor
- Sociedad Argentina de Reumatologia
Zoster, Systemic Lupus Erythematosus
Immunogenicity, Reactogenicity of Shingrix in SLE
To investigate the immunogenicity, reactogenicity and safety of 2 doses of the adjuvanted herpes zoster subunit vaccine (Shingrix) in patients with SLE in a randomized trial.
- Conditions
- Zoster, Systemic Lupus Erythematosus, Vaccine Reaction
- Trial name
- NCT06001606
- Testing
- Shingrix
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.